Vitro, a privately held company headquartered in Seville, Spain, has sold Cytognos to Becton Dickinson and Company (BD).
Vitro, a privately held company headquartered in Seville, Spain, has sold Cytognos to Becton Dickinson and Company (BD).
Cytognos is a company specialising in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for haematological diseases. Cytognos’ employees joining BD as a result of the acquisition will continue to support employment stability in the Salamanca area in Spain.
Terms of the transaction have not been disclosed.
Vitro has been a long-term investor in Cytognos since 1996, taking a majority stake in the company in 2018 to create a full platform player that integrates and commercialises flow cytometry reagents, hardware and software. This add-on investment was Vitro’s first since GED Capital’s majority investment in the company in June 2017. Cytognos has since evolved into a full platform player in the clinical flow cytometry market.
